Evidence map›Paper›PMID 27162556›Full record

ArticleTheranostics2016

Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific Antibodies.

Hua Jing, Claudia Weidensteiner, Wilfried Reichardt, Simone Gaedicke, Xuekai Zhu, Anca-Ligia Grosu, Hisataka Kobayashi, Gabriele Niedermann

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 83 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Tumor heterogeneity and resistance in glioblastoma: the role of stem cells.Apoptosis : an international journal on programmed cell death · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Hua Jing1. Dept. for Radiation Oncology, University Hospital Freiburg, D-79106 Freiburg, Germany; 3. German Cancer Consortium (DKTK), Freiburg, and German Cancer Research Centre (DKFZ), D-69121 Heidelberg, Germany.
Claudia Weidensteiner2. Radiology Medical Physics, University Hospital Freiburg, D-79106 Freiburg, Germany.
Wilfried Reichardt2. Radiology Medical Physics, University Hospital Freiburg, D-79106 Freiburg, Germany.
Simone Gaedicke1. Dept. for Radiation Oncology, University Hospital Freiburg, D-79106 Freiburg, Germany.
Xuekai Zhu1. Dept. for Radiation Oncology, University Hospital Freiburg, D-79106 Freiburg, Germany; 3. German Cancer Consortium (DKTK), Freiburg, and German Cancer Research Centre (DKFZ), D-69121 Heidelberg, Germany.
Anca-Ligia Grosu1. Dept. for Radiation Oncology, University Hospital Freiburg, D-79106 Freiburg, Germany; 3. German Cancer Consortium (DKTK), Freiburg, and German Cancer Research Centre (DKFZ), D-69121 Heidelberg, Germany.
Hisataka Kobayashi4. Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Gabriele Niedermann1. Dept. for Radiation Oncology, University Hospital Freiburg, D-79106 Freiburg, Germany; 3. German Cancer Consortium (DKTK), Freiburg, and German Cancer Research Centre (DKFZ), D-69121 Heidelberg, Germany.
University Medical Center Freiburg · DEHeidelberg University · DENational Cancer Institute · US

Funding

Cancer-cell specific therapy: photo-immunotherapyZIABC011513 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KOBAYASHI, HISATAKA · 2013 to 2025
$15.5M
6 · The paper itself

Abstract

Near-infrared photoimmunotherapy (NIR-PIT), which employs monoclonal antibody (mAb)-phototoxic phthalocyanine dye IR700 conjugates, permits the specific, image-guided and spatiotemporally controlled elimination of tumor cells. Here, we report the highly efficient NIR-PIT of human tumor xenografts initiated from patient-derived cancer stem cells (CSCs). Using glioblastoma stem cells (GBM-SCs) expressing the prototypic CSC marker AC133/CD133, we also demonstrate here for the first time that NIR-PIT is highly effective against brain tumors. The intravenously injected theranostic AC133 mAb conjugate enabled the non-invasive detection of orthotopic gliomas by NIR fluorescence imaging, and reached AC133+ GBM-SCs at the invasive tumor front. AC133-targeted NIR-PIT induced the rapid cell death of AC133+ GBM-SCs and thereby strong shrinkage of both subcutaneous and invasively growing brain tumors. A single round of NIR-PIT extended the overall survival of mice with established orthotopic gliomas by more than a factor of two, even though the harmless NIR light was applied through the intact skull. Humanised versions of this theranostic agent may facilitate intraoperative imaging and histopathological evaluation of tumor borders and enable the highly specific and efficient eradication of CSCs.

Indexed as

AC133 AntigenAnimalsAntibodiesBrain NeoplasmsDisease Models, AnimalGlioblastomaHeterograftsHumansImmunotherapyIndolesIsoindolesMicePhototherapyStem CellsSurvival AnalysisTheranostic NanomedicineAC133 AntigenAntibodiesIndolesIsoindolesphthalocyanineProm1 protein, mousecancer stem cellsCD133glioblastomanear-infrared photoimmunotherapy

Identifiers

PMID27162556
PMCPMC4860894
OpenAlexW2343465088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.